This Aβ accumulation reduction may result from enhanced astrocytic endocytosis facilitated by Mt3 activation,[7] highlighting the potential of this targeted approach in alleviating Aβ pathology in AD models. The gene discussed is MT3; the disease is Alzheimer disease.